Business Context and Reporting Period
Tvardi Therapeutics, Inc. (TVRD) is a clinical-stage biopharmaceutical company developing oral, small molecule STAT3 inhibitors (TTI-101 and TTI-109) for inflammatory and proliferative diseases. This Form 10-Q covers the quarterly period ended June 30, 2026. The Company is a smaller reporting company and has no products approved for commercial sale.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6.5) million | $(13.3) million |
| Operating Expenses | $6.6 million | $13.7 million |
| Cash and Cash Equivalents (End of Period) | $15.8 million | $15.8 million |
| Net Cash Used in Operating Activities | N/A | $(15.1) million |
| Accumulated Deficit | $(123.7) million | $(123.7) million |
Note: Amounts in millions unless otherwise noted. No debt is outstanding as Convertible Notes were converted to equity in April 2025.
Material Changes vs. Prior Period
- Net Income/Loss Volatility: The Company reported a net loss of $6.5 million for the three months ended June 30, 2026, compared to net income of $4.2 million in the same period in 2025. The 2025 income was driven by a $12.7 million non-cash gain from the fair value remeasurement of Convertible Notes prior to their conversion. This non-recurring gain is absent in 2026.
- Operating Expenses: Total operating expenses decreased by 25.3% ($2.2 million) in the three-month period compared to 2025, primarily due to a $2.7 million reduction in costs for the TTI-101 Idiopathic Pulmonary Fibrosis (IPF) trial, which concluded enrollment. This was partially offset by a $0.5 million increase in TTI-109 development costs.
- Liquidity: Cash and cash equivalents decreased from $20.7 million at December 31, 2025, to $15.8 million at June 30, 2026, reflecting a net cash burn of approximately $5.0 million for the six-month period.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that conditions raise substantial doubt about the Company's ability to continue as a going concern. Current cash resources are insufficient to fund operations for at least one year from the filing date. Additional funding is required to advance clinical trials.
- Clinical Progress:
- TTI-109: Positive Phase 1 results in healthy volunteers were reported in July 2026. Ulcerative Colitis (UC) was selected as the initial disease indication.
- TTI-101: Phase 2 data in IPF did not meet primary goals, though exploratory analyses showed reductions in fibrosis markers. Topline data for the HCC Phase 1b/2 trial is expected in Q4 2026.
- Capital Raising: The Company filed a shelf registration (Form S-3) in May 2026. Subsequent to June 30, 2026, the Company sold approximately $13.3 million of common stock under At-The-Market (ATM) facilities.
- Internal Controls: The Company disclosed material weaknesses in internal control over financial reporting, including inadequate segregation of duties and lack of formal risk assessment processes. Remediation efforts are underway.
- Legal Proceedings: A complaint was filed in March 2026 alleging breach of a Registration Rights Agreement; the Company states this is not expected to have a material adverse effect.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $15.8 million cash balance against the projected burn rate and the timeline for the next capital raise.
- Subsequent Equity Sales: Confirm the dilution impact of the $13.3 million in stock sales occurring after the period end (July-August 2026).
- Internal Control Remediation: Monitor the progress of remediation for the disclosed material weaknesses in financial reporting controls.
- TTI-101 IPF Data: Review the final analysis of the IPF trial data to determine if the program will be continued or abandoned.
- License Obligations: Note the termination of the BCM Second Agreement (anaphylaxis) in April 2026 and ongoing royalty obligations under the BCM First Agreement.